AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Part of paid clinical trials in Duarte, California.

Sponsor
Arsenal Biosciences, Inc.
Study ID
NCT07285694
Phase
PHASE1/PHASE2
Status
Recruiting

Conditions

  • Metastatic Castration Resistant Prostate Cancer (mCRPC)

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AB-3028 — BIOLOGICAL
    autologous T cell therapy

Study Details

This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).

Key Dates

Start date
Jan 9, 2026
Status verified
Jun 2026
Primary completion
May 31, 2029
Completion
May 31, 2031

Study Design

Enrollment
190 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: AB-3028
    Patients receive a single dose of AB-3028 intravenously on day 0.

Primary Outcome Measure

Safety and tolerability of AB-3028 [ Time Frame: From AB-3028 infusion up to 24 months post-infusion ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010
Clinical Trials Line
626-218-1133
USC Norris Comprehensive Cancer CenterLos AngelesCalifornia90033
Clinical Investigation Support Office
323-865-0451
University of California, San FranciscoSan FranciscoCalifornia94143
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)AuroraColorado80045-
University of Iowa and Holden Comprehensive Cancer CenterIowa CityIowa52242
Clinical trial intake (Genitourinary Cancer)
The University of Kansas Cancer CenterFairwayKansas66205-
University of MinnesotaMinneapolisMinnesota55455-
Perlmutter Cancer Center - NYU Langone HealthNew YorkNew York10016-
Fred Hutchinson Cancer CenterSeattleWashington98109
Fred Hutch Intake
206-606-1024

Find similar trials in Duarte, CA

Related Studies